Interferon ‐free therapy of chronic hepatitis C with direct‐acting antivirals does not change the short‐term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis

ConclusionsIFN‐free direct‐acting antiviral therapy of chronic hepatitis C does not alter the short‐term risk for HCC in patients with liver cirrhosis. A reduced HCC incidence may become evident after more than 1.5 years of follow‐up.

Source: Alimentary Pharmacology and Therapeutics - December 4, 2017 Category: Drugs & Pharmacology Authors: F. Mettke, B. Schlevogt, K. Deterding, A. Wranke, A. Smith, K. Port, M.  P. Manns, A. Vogel, M. Cornberg, H. Wedemeyer Tags: ORIGINAL ARTICLE Source Type: research